{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:13:28Z","timestamp":1784333608630,"version":"3.55.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T00:00:00Z","timestamp":1508112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Although opioid-induced nausea and vomiting (OINV) often result in analgesic undertreatment in patients with cancer, no randomized controlled trials have evaluated the efficacy of prophylactic antiemetics for preventing OINV. We conducted this randomized, placebo-controlled, double-blind trial to evaluate the efficacy and safety of prophylactic treatment with prochlorperazine for preventing OINV.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Cancer patients who started to receive oral oxycodone were randomly assigned in a 1:1 ratio to receive either prochlorperazine 5 mg or placebo prophylactically, given three times daily for 5 days. The primary endpoint was the proportion of patients who had a complete response (CR) during the 120 hours of oxycodone treatment. CR was defined as no emetic episode and no use of rescue medication for nausea and vomiting during 5 days. Key secondary endpoints were the proportion of patients with emetic episodes, proportion of patients with moderate or severe nausea, quality of life, and proportion of treatment withdrawal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From November 2013 through February 2016, a total of 120 patients were assigned to receive prochlorperazine (n\u2009=\u200960) or placebo (n\u2009=\u200960). There was no significant difference in CR rates (69.5% vs. 63.3%; p\u2009=\u2009.47) or any secondary endpoint between the groups. Patients who received prochlorperazine were more likely to experience severe somnolence (p\u2009=\u2009.048).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Routine use of prochlorperazine as a prophylactic antiemetic at the initiation of treatment with opioids is not recommended. Further research is needed to evaluate whether other antiemetics would be effective in preventing OINV in specific patient populations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Prophylactic prochlorperazine seems to be ineffective in preventing opioid-induced nausea and vomiting (OINV) and may cause adverse events such as somnolence. Routine use of prophylactic prochlorperazine at the initiation of treatment with opioids is not recommended. Further research is needed to evaluate whether other antiemetics would be effective in preventing OINV in specific patient populations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0225","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T01:05:19Z","timestamp":1508202319000},"page":"367-374","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial"],"prefix":"10.1093","volume":"23","author":[{"given":"Hiroaki","family":"Tsukuura","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Aichi, Japan"},{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Palliative and Supportive Care, Palliative Care Team and Seirei Hospice, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihoko","family":"Sugishita","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Murasaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishal","family":"Gyawali","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kubo","sequence":"additional","affiliation":[{"name":"Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ando","sequence":"additional","affiliation":[{"name":"Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyofumi","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,10,16]]},"reference":[{"key":"2021122510435961600_onco12284-bib-0001","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdm056","article-title":"Prevalence of pain in patients with cancer: A systematic review of the past 40 years","volume":"18","author":"den Beuken-van Everdingen","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122510435961600_onco12284-bib-0002","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/annonc\/mdp001","article-title":"Cancer-related pain: A pan-European survey of prevalence, treatment, and patient attitudes","volume":"20","author":"Breivik","year":"2009","journal-title":"Ann Oncol"},{"key":"2021122510435961600_onco12284-bib-0003","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","article-title":"Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis","volume":"51","author":"den Beuken-van Everdingen","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"2021122510435961600_onco12284-bib-0004","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","article-title":"Use of opioid analgesics in the treatment of cancer pain: Evidence-based recommendation from the EAPC","volume":"13","author":"Caraceni","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021122510435961600_onco12284-bib-0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/annonc\/mds233","article-title":"Management of cancer pain: ESMO Clinical Practice Guidelines","volume":"23","author":"Ripamonti","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122510435961600_onco12284-bib-0006","doi-asserted-by":"crossref","first-page":"992","DOI":"10.6004\/jnccn.2013.0119","article-title":"Adult cancer pain","volume":"11","author":"Swarm","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122510435961600_onco12284-bib-0007","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1526-5900(03)00556-X","article-title":"Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review","volume":"4","author":"McNicol","year":"2003","journal-title":"J Pain"},{"key":"2021122510435961600_onco12284-bib-0008","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0140-6736(92)90546-F","article-title":"Cancer pain: Management","volume":"339","author":"Hanks","year":"1992","journal-title":"Lancet"},{"key":"2021122510435961600_onco12284-bib-0009","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/0269216311404273","article-title":"Management of opioid-induced nausea and vomiting in cancer patients: Systematic review and evidence-based recommendations","volume":"25","author":"Laugsand","year":"2011","journal-title":"Palliat Med"},{"key":"2021122510435961600_onco12284-bib-0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00003495-200363010-00002","article-title":"Responsible prescribing of opioids for the management of chronic pain","volume":"63","author":"Nicholson","year":"2003","journal-title":"Drugs"},{"key":"2021122510435961600_onco12284-bib-0011","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1200\/JCO.2001.19.9.2542","article-title":"Strategies to manage the adverse effects of oral morphine: An evidence-based report","volume":"19","author":"Cherny","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122510435961600_onco12284-bib-0012","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"29","author":"Basch","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122510435961600_onco12284-bib-0013","first-page":"3458","year":"2006"},{"key":"2021122510435961600_onco12284-bib-0014","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/EJA.0b013e328352813f","article-title":"Low-dose droperidol (\u22641 mg or \u226415 \u03bcg kg-1) for the prevention of postoperative nausea and vomiting in adults: Quantitative systematic review of randomized controlled trials","volume":"29","author":"Schaub","year":"2012","journal-title":"Eur J Anaesthesiol"},{"key":"2021122510435961600_onco12284-bib-0015","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1742-6723.2011.01433.x","article-title":"Review article: Prophylactic metoclopramide for patients receiving intravenous morphine in the emergency setting: A systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Simpson","year":"2011","journal-title":"Emerg Med Australas"},{"key":"2021122510435961600_onco12284-bib-0016","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s00520-009-0775-3","article-title":"Pharmaceutical interventions facilitate premedication and prevent opioid-induced constipation and emesis in cancer patients","volume":"18","author":"Ishihara","year":"2010","journal-title":"Support Care Cancer"},{"key":"2021122510435961600_onco12284-bib-0017","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/AJP.0b013e318237d626","article-title":"A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction","volume":"28","author":"Ishihara","year":"2012","journal-title":"Clin J Pain"},{"key":"2021122510435961600_onco12284-bib-0018","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/jpm.2013.0613","article-title":"Predictive factors for nausea or vomiting in patients with cancer who receive oral oxycodone for the first time: Is prophylactic medication for prevention of opioid-induced nausea or vomiting necessary?","volume":"17","author":"Kanbayashi","year":"2014","journal-title":"J Palliat Med"},{"key":"2021122510435961600_onco12284-bib-0019","doi-asserted-by":"crossref","first-page":"431","DOI":"10.5055\/jom.2010.0041","article-title":"A retrospective chart review of opioid-induced nausea and somnolence on commencement for cancer pain treatment","volume":"6","author":"Okamoto","year":"2010","journal-title":"J Opioid Manag"},{"key":"2021122510435961600_onco12284-bib-0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cca.2013.12.011","article-title":"Impact of genetic and non-genetic factors on clinical responses to prochlorperazine in oxycodone-treated cancer patients","volume":"429","author":"Tashiro","year":"2014","journal-title":"Clin Chim Acta"},{"key":"2021122510435961600_onco12284-bib-0021","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1089\/jpm.2015.0203","article-title":"Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: A questionnaire survey among Japanese physicians","volume":"18","author":"Tsukuura","year":"2015","journal-title":"J Palliat Med"},{"key":"2021122510435961600_onco12284-bib-0022","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00520-016-3371-3","article-title":"2016 Updated MASCC\/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer","volume":"25","author":"Walsh","year":"2017","journal-title":"Support Care Cancer"},{"key":"2021122510435961600_onco12284-bib-0023","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"2021122510435961600_onco12284-bib-0024","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/082585979100700202","article-title":"The Edmonton Symptom Assessment System (ESAS): A simple method for the assessment of palliative care patients","volume":"7","author":"Bruera","year":"1991","journal-title":"J Palliat Care"},{"key":"2021122510435961600_onco12284-bib-0025","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jpainsymman.2015.05.014","article-title":"Validation of the Japanese version of the Edmonton Symptom Assessment System-Revised","volume":"50","author":"Yokomichi","year":"2015","journal-title":"J Pain Symptom Manage"},{"key":"2021122510435961600_onco12284-bib-0026","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2005.06.022","article-title":"The development of the EORTC QLQ-C-15-PAL: A shortened questionnaire for cancer patients in palliative care","volume":"42","author":"Groenvold","year":"2006","journal-title":"Eur J Cancer"},{"key":"2021122510435961600_onco12284-bib-0027","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jpainsymman.2014.11.299","article-title":"Independent validation of the Japanese version of the EORTC QLQ-C-15-PAL for patients with advanced cancer","volume":"49","author":"Miyashita","year":"2015","journal-title":"J Pain Symptom Manage"},{"key":"2021122510435961600_onco12284-bib-0028","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/annonc\/mdp195","article-title":"A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy","volume":"20","author":"Maemondo","year":"2009","journal-title":"Ann Oncol"},{"key":"2021122510435961600_onco12284-bib-0029","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/annonc\/mds541","article-title":"Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: A multicentre, randomized, double-blind, placebo-controlled phase 3 trial","volume":"24","author":"Saito","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122510435961600_onco12284-bib-0030","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jpainsymman.2015.09.011","article-title":"Establishing cutoff points for defining symptom severity using the Edmonton Symptom Assessment System-Revised Japanese Version","volume":"51","author":"Yamaguchi","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"2021122510435961600_onco12284-bib-0031","author":"National Cancer Institute","year":"2009"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0225","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0225","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/3\/367\/41915378\/oncolo_23_3_367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/3\/367\/41915378\/oncolo_23_3_367.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:45:46Z","timestamp":1640429146000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/3\/367\/6439295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,16]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,10,16]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0225","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3,1]]},"published":{"date-parts":[[2017,10,16]]}}}